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Protein phosphatase 1α (PP1α) regulates phosphorylation of BRCA1, which contains a PP1-binding motif 
898KVTF901. Mutation of this motif greatly reduces the interaction between BRCA1 and PP1α. Here we show that 
mutation of the PP1-binding motif abolishes the ability of BRCA1 to enhance survival of Brca1-deficient mouse 
mammary tumor cells after DNA damage. The Rad51 focus formation and comet assays revealed that the DNA 
repair function of BRCA1 was impaired when the PP1-binding motif was mutated. Analysis of subnuclear 
localization of GFP-tagged BRCA1 demonstrated that mutation of the PP1-binding motif affected BRCA1 
redistribution in response to DNA damage. BRCA1 is required for the formation of Rad51 subnuclear foci after 
DNA damage. Mutation of the PP1-binding motif in BRCA1 also affected recruitment of Rad51 to sites of DNA 
damage. Consistent with these findings, knockdown of PP1α in BRCA1-proficient cells by small interfering RNA 
also significantly reduced Rad51 focus formation induced by DNA damage. Further analysis indicated that 
mutation of the PP1-binding motif compromised BRCA1 activities in homologous recombination. Altogether, 
our data implicate that interaction with PP1α is important for BRCA1 function in DNA repair.   
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1. Introduction 
Mutations of the human breast and ovarian can-
cer susceptibility gene BRCA1 account for the majority 
of familial breast and ovarian cancer cases. The BRCA1 
gene encodes a nuclear phosphoprotein of 1863 amino 
acids (Mr ~220,000). Accumulated evidence indicates 
that BRCA1 plays an important role in multiple cellu-
lar functions including cell cycle checkpoint control, 
chromosome remodeling, transcriptional regulation, 
recombination, and DNA repair; therefore, is crucial 
for maintaining genomic integrity and chromosomal 
stability [1-3]. 
BRCA1 is expressed and phosphorylated in a cell 
cycle-dependent manner and is mainly phosphory-
lated in S phase [4,5]. BRCA1 is also phosphorylated 
by checkpoint kinases, including hCds1/Chk2, ATM, 
and ATR, in response to DNA damage induced by 
ionizing radiation (IR), UV or chemicals. Phosphoryla-
tion of BRCA1 occurs at multiple serine residues, such 
as S1524 and S1423 by ATM and ATR [6-9] and S988 
by hCds1/Chk2 [10]. The phosphorylation state of 
BRCA1 is important for its function in G2/M check-
point control [11] and DNA repair [12]. However, 
BRCA1 is primarily hypophosphorylated in mitosis 
and G0/G1 phases of the cell cycle [5,13], suggesting 
that BRCA1 must undergo dephosphorylation during 
G2/M transition. Whether or not dephosphorylation 
of BRCA1 is critical for its function remains unclear.   
Serine/threonine protein phosphatase 1 (PP1) 
holoenzymes consist of catalytic subunits and regula-
tory subunits which target the catalytic subunits to 
distinct subcellular localizations. Together, the PP1 
complexes regulate diverse cellular functions includ-
ing cell cycle progression, chromosome segregation, 
cytokinesis, and cellular metabolism [14]. Recent 
studies also indicate that PP1 is involved in check-
point activation [15] and DNA repair [16], as well as 
recovery from DNA damage checkpoint arrest [17]. 
We previously reported that the PP1α catalytic sub-
unit interacts with BRCA1 and dephosphorylates the 
protein at multiple serine residues that are phos-
phorylated by hCds1/Chk2, ATM and ATR [18,19]. 
Thus, PP1α, one of the three isoforms of the PP1 cata-Int. J. Biol. Sci. 2008, 4 
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lytic subunit (α,  γ, and δ), may serve as a general 
regulator for BRCA1 phosphorylation.   
Proteins interacting with the PP1 catalytic sub-
unit, including the majority of regulatory subunits and 
several substrates, share a consensus PP1-binding mo-
tif (R/K)(V/I)xF, which binds to a hydrophobic 
groove on the surface of the PP1 catalytic subunit and 
serves as an anchor for the initial binding of these 
proteins to PP1 [14]. Mutation of this consensus motif 
by substitution of phenylalanine with alanine or dele-
tion of the motif greatly reduces the binding between 
these proteins and the PP1 catalytic subunit. We re-
cently identified a PP1-binding motif 898KVTF901 in 
human BRCA1. Mutation of this motif substantially 
reduces the interaction between BRCA1 and PP1α 
[19].  
BRCA1 is implicated in the repair of DNA dou-
ble-strand breaks (DSBs) by either homologous re-
combination (HR) or non-homologous end-joining 
(NHEJ) [1,2,20]. It has been reported that BRCA1 also 
participates in nucleotide-excision repair [21,22]. 
Rad51, a homologue of bacterial RecA protein, is in-
volved in the repair of DSBs by HR, which is an er-
ror-free DNA repair process. Expression of Rad51 is 
also cell cycle-dependent [23] and the protein forms 
nuclear foci in S phase [24]. BRCA2 has been shown to 
interact with Rad51 and regulate the assembly of 
Rad51 filaments at the sites of DNA repair. BRCA1 
forms a complex with both Rad51 [25] and BRCA2 
[26]. BRCA1 associates with Rad51 at subnuclear foci 
[25]. After DNA damage, BRCA1 is phosphorylated, 
relocalizes along with Rad51 to the damaged regions, 
and displays large nuclear foci [27,28]. BRCA1 also 
associates with the MRE11/RAD50/NBS1 complex, 
which participates in HR, NHEJ, and the DNA dam-
age response [28]. It has been demonstrated that 
hCds1/Chk2 phosphorylation of BRCA1 regulates the 
repair of DSBs by promoting error-free HR and sup-
pressing error-prone NHEJ [12]. BRCA1 may also par-
ticipate in an error-free subtype of NHEJ [29,30]. Thus, 
BRCA1 is required for accurate DNA repair and 
BRCA1-deficient cells are hypersensitive to DNA 
damaging agents which induce DSBs or crosslinks of 
DNA strands. Here, we sought to test whether inter-
action with PP1 was involved in the DNA repair func-
tion of BRCA1 using Brca1∆11/∆11 mouse mammary 
tumor cells [31]. 
2. Materials and Methods 
Vector construction  
To construct pGFPBRCA1, a ~5.6 kb XhoI-HindIII 
BRCA1 cDNA fragment containing the human BRCA1 
cDNA sequence (containing the stop codon) was sub-
cloned into pGFP-C3 (Clontech, Mountain View, CA, 
USA). The mutant BRCA1 expression vectors, 
pGFPBRCA1F901A and pGFPBRCA1DEL, were con-
structed by replacing a 4.2 kb AflII-HindIII fragment in 
pGFPBRCA1 with the same fragments containing the 
mutations from modified pBRCA1GFPF901A and 
pBRCA1GFPDEL with the BRCA1 stop codon. All 
plasmid clones were sequence-verified. 
Cell culture and transfection  
A mouse mammary tumor cell line 780 (Brca1 
exon 11-deleted), 293T and COS-7 cells were cultured 
in DMEM supplemented with 2 mM L-glutamine and 
10% FBS, and ES-2 cells were cultured in McCoy’s 5A 
medium supplemented with 1.5 mM L-glutamine and 
10% FBS. Transfection was performed using Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. Cells were 
harvested for analysis 24-48 h after transfection. Tar-
get-specific 20-25 nucleotide small interfering RNAs 
(siRNAs) for human PP1α and control siRNA were 
purchased from Santa Cruz (CA, USA) and siRNA 
transfection was also performed using Lipofectamine 
2000. 
Analysis of cell cycle distribution by flow cytometry 
Cells were harvested by trypsinization, fixed in 
ice-cold methanol, and subjected to propidium iodide 
staining and flow cytometric analysis as described 
previously [32]. 
Western analysis  
Cells were harvested by trypsinization and lysed 
in RIPA buffer supplemented with protease inhibitors. 
Cell lysates containing ~100 μg of protein were sub-
jected to 4-12% SDS-PAGE, followed by Western 
analysis. Antibodies used were human BRCA1 anti-
body Ab-1 (MS110) (Calbiochem, San Diego, CA, 
USA), mouse Brca1 M-20, PP1α C-19, Rad51 H-92 an-
tibodies (Santa Cruz), and γ-tubulin antibody GTU-88 
(Sigma, St Louis, MO, USA). Quantitative analysis was 
performed using Quantity One software (BioRad, 
Hercules, CA, USA). 
Cell survival assay  
Cell survival was measured by colony formation. 
One day after transfection, 500 or 1000 cells were 
seeded in T-25 flasks. The next day, cells were either 
left untreated (C) or exposed to 5 Gy of IR from a 137Cs 
source (Sheperd Mark I 30-1 Irradiator) at a dose rate 
of ~110 cGy/min. Two weeks after IR treatment, colo-
nies were fixed in cold methanol and stained with 
Giemsa. Colonies with at least 50 cells were then 
s c o r e d .  R e l a t i v e  c e l l  s u r v i v a l  w a s  c a l c u l a t e d  a s  t h e  
ratio of colony numbers in irradiated and untreated 
groups (IR/C).   Int. J. Biol. Sci. 2008, 4 
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Immunofluorescence staining  
Cells were seeded into 4-well or 8-well chamber 
slides. The next day, cells were either left untreated or 
treated with 100 μM of 5-fluorodeoxyuridine (5-FUdR) 
or irradiated with 5 Gy of IR. After 24 h-treatment in 
5-FUdR or 3 h, 6 h and 12 h after exposure to IR, cells 
were fixed on ice for 30 min in PBS-buffered 3% para-
formaldehyde/2% sucrose solution and permeabilized 
for 5 min in cold Triton buffer (0.5% Triton X-100 in 20 
mM HEPES, pH 7.4, 50 mM NaCl, 3 mM MgCl2, 300 
mM sucrose)[27]. Antibody incubation was carried out 
as described previously [32,33]. Primary antibody 
used was a rabbit polyclonal anti-Rad51 (1:100 to 1:200 
dilution, Santa Cruz) and secondary antibody used 
was FITC or Texas red-conjugated anti-rabbit at a di-
lution of 1:200. All slides were counter-stained with 
DAPI and mounted with antifade (Invitrogen). Ap-
proximately 500 cells were scored and the percentages 
of cells with at least ten Rad51 nuclear foci were cal-
culated. 
Comet assay  
Cells were treated with IR (5 Gy) and subjected 
to the alkaline comet assay (single-cell gel electropho-
resis) 24 h after irradiation according to the manufac-
turer’s protocol (Trevigen, Gaithersburg, MD). Comet 
images were captured using a fluorescence micro-
scope with a 20× objective (Carl Zeiss Inc., Chester, 
VA) and the comet tail moment (an index of DNA 
damage calculated as the product of tail length and 
fraction of DNA in the comet tail) was evaluated using 
Cometscore version 1.5 software (AutoComet.com). At 
least 50 cells were analyzed for each sample in each 
experiment to calculate the mean tail moment. 
Homologous recombination assay  
To generate cell clones carrying a substrate plas-
mid for the HR assay, 780 cells were transfected with 1 
μg of linearized pDT220 and stable cells were selected 
with 5 µg/ml of puromycin. Southern blot analysis 
was used to identify cell clones carrying a single copy 
of the pDT220 substrate as described [12]. A cell clone 
780
pDT220, which showed two bands after EcoRV diges-
tion (an indication of single copy insertion of pDT220), 
was selected for the HR assay. To determine chromo-
somal HR, 780
pDT220 cells were co-transfected with ei-
ther wild-type or mutant pBRCA1GFP and either 
pCMV-I-SceI or a control vector in 60-mm dishes. Cells 
were trypsinized and transferred to 100-mm dishes 
two days after transfection, and were allowed to at-
tach to the dishes for one day. Cells were then selected 
with XHATM (250 µg/ml xanthine, 13.6 µg/ml hy-
poxanthine, 0.17 µg/ml aminopterin, 3.87 µg/ml 
thymidine, and 10 μg/ml mycophenolic acid)(Sigma) 
for three weeks. Colonies were fixed and stained with 
Giemsa. XHATM-resistant colonies (at least 50 cells 
per colony) were quantified. The HR frequency was 
calculated as the number of resistant colonies divided 
by the number of cells seeded (5 × 105 in each 100-mm 
dish). 
Non-homologous end-joining assay 
780 cells were plated in 6-well plates, and 
co-transfected with a linearized hyg expression vector 
and wild-type or mutant BRCA1GFP expression vec-
tor the next day. Cells were trypsinized and 5 × 105 
cells were transferred into 100-mm dishes 24 h after 
transfection and subjected to selection one day later 
with 500 μg/ml hygromycin B for 2-3 weeks. Colonies 
were stained with Giemsa and counted. The NHEJ 
frequency was calculated as the number of resistant 
colonies divided by the number of cells seeded. 
Statistical analysis  
Data were presented as mean ± SD. Two-sided 
t-tests were used to assess the significance of the data. 
P-values < 0.05 were considered statistically signifi-
cant (marked with “ * ” in the figures).     
3. Results 
A functional PP1-binding motif is important for BRCA1 
to enhance survival of Brca1-deficient mouse mam-
mary tumor cells after DNA damage 
We previously demonstrated that transient ex-
pression of wild-type but not PP1-binding motif mu-
tated (F901A) or deleted (DEL) human BRCA1GFP 
protein increased cell survival after DNA damage in a 
BRCA1-deficient breast cancer cell line HCC1937 [19]. 
Because the coding sequences for the PP1-binding 
motif  898KVTF901 is located in exon 11, we sought to 
confirm this finding in a Brca1 exon 11-deleted 
(Brca1∆11/∆11) mouse mammary tumor cell line 780 [31] 
and study the underlying mechanisms.   
The full-length (FL) mouse Brca1 protein consists 
of 1812 amino acids [34,35]. Deletion of exon 11 leads 
to an in-frame loss of nucleotide sequences encoding 
1105 amino acids and results in a truncated protein of 
707 amino acids. As shown in Fig. 1A, 780 cells only 
expressed a truncated, but not a FL Brca1 protein de-
tected by Western blot analysis using an antibody 
M-20, which recognizes the C-terminus of mouse 
Brca1. Transfection efficiency in 780 was determined 
using a green fluorescent protein (GFP) expression 
vector pEGFP-N1 and was in the range of 50-75%, 
which was much better than the transfection efficiency 
in HCC1937 cells. Expression of wild-type and mutant 
(F901A and DEL) BRCA1GFP proteins in 780 cells was 
monitored by Western analysis using a human BRCA1 Int. J. Biol. Sci. 2008, 4 
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antibody MS110 for every transfection experiment and 
the expression levels were similar (Fig. 1A). Transient 
expression of wild-type or mutant BRCA1GFP protein 
in 780 cells was consistent and did not change cell cy-
cle distribution; whereas, protein expression in stable 
c e l l  c l o n e s  t e n d e d  t o  d i m i n i s h  o v e r  t i m e  ( d a t a  n o t  
shown). Therefore, we performed the functional as-
says using transiently transfected cells. 
 
 
Figure 1. A PP1-binding motif is important for BRCA1 to 
enhance survival of Brca1-deficient mouse mammary tumor 
cells after γ-irradiation. (A) Expression of exogenous human 
BRCA1GFP and endogenous truncated mouse Brca1 in tran-
siently transfected 780 cells. (B) Cell survival measured by 
colony formation. 780 cells were transfected with empty vector 
pEGFP-N1KS- (EV), wild-type pBRCA1GFP (WT), 
pBRCA1GFPF901A (F901A), and pBRCA1GFPDEL (DEL), 
followed by exposure to 5 Gy of IR. The assay was performed at 
least three times and similar results were obtained. * P < 0.05 
 
We next examined whether expression of 
wild-type, F901A or DEL mutant BRCA1GFP affected 
survival of 780 cells after exposure to γ-radiation. 
Transfected 780 cells were treated with 5 Gy of IR or 
without irradiation (C), and cell survival was meas-
ured by colony formation two weeks after 
γ-irradiation. As shown in Fig. 1B, relative cell sur-
vival (IR/C) was 8.5% in empty vector-transfected 
cells, and was significantly increased to 14.3% (a ~70% 
increase) in wild-type pBRCA1GFP-transfected cells 
(P = 0.00014, two-sided t test). Our data was compara-
ble to the report by Scully et al., which demonstrated 
that expression of wild-type BRCA1 increased relative 
cell survival by 50-100% in HCC1937 cells exposed to 
3-4 Gy of IR [36]. In contrast, expression of mutant 
BRCA1GFP, F901A and DEL, resulted in 8.6% and 
7.9% relative cell survival respectively, which were 
similar to empty vector-transfected cells and signifi-
cantly lower than the survival in wild-type 
pBRCA1GFP-transfected cells (P = 0.000295, F901A vs. 
wild-type; P = 0.00017, DEL vs. wild-type). Thus, con-
sistent with our previous finding in HCC1937 cells 
[19], reconstitution of F901A or DEL mutant BRCA1 
protein in Brca1-deficient 780 cells did not enhance 
survival after γ-irradiation. 
Mutation of the PP1-binding motif in BRCA1 affects its 
DNA repair function  
BRCA1 phosphorylation by checkpoint kinases 
in response to DNA damage is involved in the re-
cruitment of DNA repair proteins including Rad51 to 
DNA lesions. Rad51 focus formation in the nucleus 
increases after DNA damage and serves as an indica-
tion of DNA repair. To determine whether the 
PP1-binding motif was critical for BRCA1 function in 
DNA repair, 780 cells were transfected with an empty 
vector, or pBRCA1GFP (wild-type, F901A, or DEL), 
left untreated (C) or treated with 5 Gy of IR, and sub-
jected to immunofluorescence staining of Rad 51 at 
various time points after IR treatment. Fig. 2A shows a 
control cell with no Rad51 foci and an IR-treated cell 
with multiple nuclear Rad51 foci. Green fluorescence 
represents the Rad51 signal. The GFP signal of 
BRCA1GFP was undetectable because it was 
quenched in the fusion proteins. Quantitative analysis 
revealed that the percentage of cells with Rad51 foci 
(defined as cells with at least 10 Rad51 foci)[28] in-
creased dramatically after exposure to IR, and the in-
crease was significantly higher in wild-type 
pBRCA1GFP-transfected cells (45.5%) than empty 
vector (20.0%), pBRCA1GFPF901A (25.8%), or 
pBRCA1GFPDEL-transfected cells (26.0%) 3 h after 
γ-irradiation (Fig. 2B). The percentage of cells with 
Rad51 foci declined 6 h and 12 h after IR. Neverthe-
less, wild-type BRCA1GFP expressing cells still 
showed a significantly higher percentage of cells with 
Rad51 foci compared to others 6 h after IR. A similar 
trend was observed at 12 h after IR treatment, al-
though the difference between wild-type and mutant 
BRCA1GFP expressing cells was not statistically sig-




Figure 2. Mutation of the PP1-binding motif in BRCA1 affects 
Rad51 focus formation after γ-irradiation. (A) A control 780 cell 
with no Rad51 foci and an IR-treated cell with multiple nuclear 
Rad51 foci. Green: Rad51, blue: DAPI counterstaining of the 
nucleus. (B) The percentage of transiently transfected 780 cells 
with Rad51 foci (defined as cells with ≥ 10 Rad51 nuclear foci) 
at various time points after exposure to 5 Gy of IR. EV, empty 
vector pEGFP-N1KS-; WT, wild-type pBRCA1GFP; F901A, 
pBRCA1GFPF901A; DEL, pBRCA1GFPDEL.  
 
The alkaline comet assay was also performed to 
measure DNA strand breaks induced by IR in 780 cells 
expressing wild-type and mutant BRCA1GFP. DNA 
damage was indicated by the comet tail moment, 
which is the product of tail length and fraction of 
DNA in the comet tail. As illustrated in Fig. 3, 24 h 
after exposure to 5 Gy of IR, empty vector-transfected 
780 cells showed a tail moment of 4.03. Expression of 
wild-type BRCA1GFP reduced the tail moment to 0.84 
(P = 0.014). In contrast, mutant BRCA1GFP (F901A 
and DEL) expressing cells displayed tail moments of 
3.65 and 3.06, which were not significantly different 
from empty vector-transfected cells. Thus, expression 
of wild-type but not mutant BRCA1GFP enhanced 
DNA repair in 780 cells.   
Taken together, results from both the Rad51 fo-
cus formation assay and the comet assay provide 
strong evidence to support that the PP1-binding motif 
in BRCA1 is important for its DNA repair function. 
 
Figure 3. Wild-type, but not PP1-non-binding mutant BRCA1 
enhances the repair of DNA strand breaks in 780 cells deter-
mined by the comet assay. Transfected cells were exposed to 5 
Gy of IR and harvested for the comet assay 24 h after irradiation.   
 
Interaction with PP1α is important for BRCA1 to 
recruit Rad51 to sites of DNA damage 
It has been reported that BRCA1 is required for 
the formation of Rad51 subnuclear foci after DNA 
damage [37]. We then tested whether interaction of 
BRCA1 with PP1α affected subcellular redistribution 
of BRCA1 and Rad51 after DNA damage. 5-FUdR, 
which showed a similar effect as IR on Rad51 focus 
formation, was used to induce DNA damage.   
As mentioned earlier, when GFP was fused to the 
carboxy terminus of BRCA1, the green fluorescence of 
the fusion protein (BRCA1GFP) was greatly quenched. 
In order to improve the green fluorescent signal of the 
fusion proteins, we constructed a series of wild-type 
and mutant GFPBRCA1 expression vectors by 
inserting the BRCA1 coding sequences downstream 
from the GFP coding sequences using the pGFP-C3 
vector. This series of expression vectors worked simi-
larly as the pBRCA1GFP vectors in functional assays 
(data not shown). As shown in Fig. 4A, when 
expressed in COS-7 cells, wild-type GFPBRCA1 
protein frequently formed large nuclear GFP foci after 
cells were treated with 100 μM of 5-FUdR for 24 h, 
whereas, mutant proteins usually appeared as small 
foci. The difference was not due to variations in 
GFPBRCA1 expression levels (Fig. 4B), but might be 
because mutant proteins were less capable to 
redistribute to DNA damage sites. Indeed, 
quantitative analysis revealed that more wild-type 
GFPBRCA1 expressing cells displayed 10 or more 
nuclear GFP foci after 5-FUdR treatment (19.1%) than 
mutant GFPBRCA1 expressing cells (6.7% and 8.8% 
respectively for F901 and DEL) as illustrated in Fig. 
4C. Unlike GFPBRCA1 proteins, GFP alone did not Int. J. Biol. Sci. 2008, 4 
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form nuclear foci (EV in Fig. 4A). Interestingly, both 
wild-type and mutant GFPBRCA1 colocalized with 
Rad51 (Fig. 4A), suggesting that the mutation does not 
affect BRCA1 interaction with Rad51.   
 
 
Figure 4. PP1-non-binding mutant BRCA1 proteins are defective in relocalization to DNA damage sites. (A) Formation of 
GFPBRCA1 and Rad51 nuclear foci in COS-7 cells after 5-FUdR treatment. Cells were fixed and subjected to Rad51 staining. 
Green: GFP or GFPBRCA1, red: Rad51. (B) Expression of GFPBRCA1 and Rad51 proteins. γ-Tubulin serves as a loading control. 
(C) The percentage of cells with ≥ 10 GFPBRCA1 nuclear foci induced by 5-FUdR.  
 Int. J. Biol. Sci. 2008, 4 
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We also knocked down PP1α in a 
BRCA1-proficient human ovarian cancer cell line ES-2 
by siRNA and measured the formation of Rad51 foci 
after 5-FUdR treatment. Western analysis indicated 
that PP1α siRNA transfection resulted in more than a 
50% decrease in PP1α protein level, while BRCA1 and 
Rad51 protein levels were not significantly affected 
(Fig. 5A). As shown in Fig. 5B, quantitative analysis 
revealed that 42.7% of control (C) siRNA-transfected 
cells had Rad51 foci (defined as cells with ≥ 10 Rad51 
foci), whereas only 19.4% of PP1α siRNA-transfected 
cells displayed Rad51 foci after 5-FUdR treatment. As 
illustrated in Fig. 5C, PP1α siRNA transfection did not 
significantly change cell cycle distribution, excluding 
the possibility that decrease of cells with Rad51 foci by 
knockdown of PP1α was simply due to a cell cycle 
effect. Since expression of both BRCA1 and Rad51 is 
cell cycle-dependent and is induced in the S phase, the 
result from cell cycle analysis was consistent with data 
in Fig. 5A that showed similar expression levels of 
BRCA1 and Rad51 in C and PP1α siRNA-transfected 
cells.  
Altogether, these data indicate that interaction of 
BRCA1 with PP1α is important for proper relocation 
of BRCA1 and Rad51 to DNA damage sites, and 




Figure 5. Knockdown of PP1α by siRNA reduces Rad51 nu-
clear foci induced by 5-FUdR. (A) Expression of PP1α, 
BRCA1, and Rad51 in C and PP1α siRNA-transfected ES-2 
cells. (B) The percentage of ES-2 cells with Rad51 foci (defined 
as cells with ≥ 10 Rad51 nuclear foci) induced by 5-FUdR. (C) 
Cell cycle distribution of C and PP1α siRNA-transfected cells. 
Promotion of homologous recombination and sup-
pression of non-homologous end-joining by BRCA1 
are partially impaired when the PP1-binding motif in 
BRCA1 is mutated   
It has been reported that BRCA1 enhances er-
ror-free HR and inhibits error prone NHEJ to ensure 
accurate DNA repair [12]. Since DNA repair function 
of BRCA1 was impaired by mutation of the 
PP1-binding motif, we next assessed whether BRCA1 
activities in HR and NHEJ were affected by the muta-
tion. 
To perform the HR assay, we established a stable 
780 cell clone (780
pDT220) with a single copy of the lin-
earized pDT220 plasmid DNA integrated in the ge-
nome as a substrate for DSB induction and HR [12]. 
The recombination substrate pDT220 contains two 
mutated copies of the bacterial gpt gene. The upstream 
copy is inactivated by insertion of an I-SceI recognition 
site, and the downstream copy has a gene-inactivating 
3' deletion in the reverse orientation. DSB induction by 
transient transfection of an I-SceI expression vector can 
lead to gene conversion that generates a functional gpt 
gene and confers resistance to XHATM. To assess the 
effect of wild-type and mutant BRCA1 on HR, 
780
pDT220 cells were co-transfected with pBRCA1GFP 
and pCMV-I-SceI. Recombinants were detected by the 
formation of XHATM-resistant colonies and the HR 
frequency was calculated as the number of resistant 
colonies divided by the number of cells seeded. As 
shown in Fig. 6A, the spontaneous HR frequency was 
in the range of 1.33-3.67 × 10-6 in empty vector or mu-
tant pBRCA1GFP-transfected cells, and appeared to be 
higher in wild-type BRCA1GFP expressing cells at 
1.57 × 10-5. Elevated spontaneous HR frequency was 
also observed in HCC1937 cells reconstituted with 
wild-type BRCA1 [12]. In the presence of DSBs gener-
ated by the I-SceI endonuclease, the HR frequency was 
4.25 × 10-6 in empty vector-transfected cells, but in-
creased dramatically to 1.05 × 10-4 in wild-type 
pBRCA1GFP-transfected 780 cells (P < 0.05). Expres-
sion of mutant BRCA1GFP F901A and DEL resulted in 
I-SceI-induced HR frequencies of 6.6 x 10-5 and 5.7 × 
10-5, which were ~50% of the frequency in cells ex-
pressing the wild-type protein (P < 0.05, mutant vs. 
wild-type). Thus, mutation of the PP1-binding motif 
significantly reduced but not completely abolished the 
effect of BRCA1 on the promotion of I-SceI-induced 
HR. 
We next determined error-prone NHEJ by meas-
uring random integration of a linearized plasmid car-
rying the hyg gene. 780 cells were co-transfected with 
the linearized plasmid and wild-type or mutant 
pBRCA1GFP, and subjected to hygromycin selection. 
Colony formation was scored 2-3 weeks after transfec-Int. J. Biol. Sci. 2008, 4 
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tion. As shown in Fig. 6B, the NHEJ frequency in 
empty vector-transfected 780 cells was 1.85 × 10-4. The 
frequency was slightly suppressed with a frequency of 
1.45 × 10-4 ( 7 8 %  o f  t h e  e m p t y  v e c t o r  c o n t r o l )  w h e n  
wild-type BRCA1GFP was expressed (P < 0.05). The 
frequencies in cells expressing mutant BRCA1GFP 
F901A and DEL were 1.74 × 10-4 and 1.68 × 10-4, which 
were statistically different from that in wild-type 
pBRCA1GFP-transfected cells (Fig. 6B). This result 
indicates that unlike in HCC1937 cells [12], BRCA1 
only has a minor effect on suppressing NHEJ in 780 
cells and mutation of the PP1-binding motif may also 
compromise this activity. 
These data indicate that the PP1-binding motif in 
BRCA1 may play a role in enhancing DNA repair 
through promoting error-free HR and to a lesser ex-
tent suppressing error-prone NHEJ. 
 
 
Figure 6. The PP1-binding motif in BRCA1 compromises its 
DNA repair function at least in part through promoting er-
ror-free HR and to a lesser extent suppressing error-prone 
NHEJ. (A) HR assay. (B) NHEJ assay. 
4. Discussion 
Increasing evidence support the notion that 
BRCA1 plays a role as a sensor and/or an effector in 
the DNA damage repair pathway and phosphoryla-
tion of BRCA1 by checkpoint kinases is critical for this 
function [1,2]. Here we provide the first evidence to 
show that interaction with PP1α is also important for 
BRCA1 function in DNA repair. 
In this study, we show that mutant BRCA1 pro-
teins lacking a functional PP1-binding motif are defec-
tive in enhancing survival of Brca1-deficient mouse 
mammary tumor cells after DNA damage at least in 
p a r t  d u e  t o  a n  i m p a i r e d  D N A  r e p a i r  f u n c t i o n  a s  
demonstrated by the Rad51 focus formation and 
comet assays. We also found that PP1-binding 
motif-mutated BRCA1 did not relocalize as efficiently 
as wild-type BRCA1 to sites of DNA lesions. 
Consequently, the ability of BRCA1 to recruit Rad51 to 
the DNA lesions was also affected when the 
PP1-binding site was mutated. Knockdown of PP1α in 
BRCA1-proficient cells by siRNA also significantly 
reduced the percentage of cells with Rad51 foci in 
response to DNA damage. Altogether, these results 
indicate that interaction with PP1α is important for the 
BRCA1 function in DNA repair partly by modulating 
subnuclear redistribution of Rad51 after DNA 
damage.  
BRCA1 S988 phosphorylation regulates the re-
pair of DNA DSBs by promoting error-free HR and 
inhibiting error-prone NHEJ [12]. We demonstrate 
here that mutation of the PP1-binding motif 
compromises BRCA1 activities in enhancing error-free 
HR and to a lesser extent suppressing error-prone 
NHEJ assayed in Brca1-deficient mouse mammary 
tumor cells, which is consisitent with our previous 
finding that PP1α regulates S988 phsophorylation [18]. 
However, the effect was not as dramatic as S988A 
mutation in HCC1937 cells [12]. It is not clear whether 
the PP1-binding site in BRCA1 is also important for 
other DNA repair mechanisms, such as 
nucleotide-excision repair and error-free NHEJ. 
Phosphorylation of BRCA1 S1423 is important for 
G2/M checkpoint control [11]. Since PP1α also regu-
lates S1423 phosphorylation [19], it is possible that 
mutation of the PP1-binding site may affect G2/M 
checkpoint function of BRCA1. This possibility is cur-
rently under investigation. 
The PP1-binding motif is common to all PP1 
isoforms [14]. Indeed, in vitro evidence indicates that 
BRCA1 also interacts with PP1γ and PP1δ (Hsu, 
unpublished data)[38]. Thus, it is likely that 
interaction with PP1, other than PP1α, is also 
important for BRCA1 function. Future investigation is 
required to provide further supporting evidence. 
PP1-binding motif mutated BRCA1 is defective 
in DNA repair implying that dephosphorylation of 
BRCA1 may be required for proper DNA damage 
signaling or DNA repair at some point after DNA Int. J. Biol. Sci. 2008, 4 
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damage, emphasizing that proper phosphoryla-
tion/dephosphorylation of multiple serine residues in 
BRCA1 is important for BRCA1 function. Alterna-
tively, BRCA1 may serve as a regulatory subunit for 
PP1 and target PP1 to other proteins whose dephos-
phorylation is crucial for the DNA damage repair 
process. These two possibilities may not be mutually 
exclusive, and will be investigated in our future study. 
Interestingly, a missense BRCA1 mutation 
(K898E) has been found in the PP1-binding region. 
The disease relevance of this mutation is still un-
known (the Breast Cancer Information Core database). 
Nonetheless, the presence of a germline mutation that 
may affect BRCA1 binding with PP1 further strength-
ens the biological significance of our finding. We have 
also found that the PPP1CA gene on human chromo-
some 11q13, which encodes the catalytic subunit of 
PP1α, is amplified and overexpressed in oral 
squamous cell carcinoma cell lines [39], suggesting a 
role of PP1α deregulation in tumor development and 
progression. Given that BRCA1 mutations only ac-
count for a small proportion of breast and ovarian 
cancers, deregulation of PP1α or other PP1 isoforms 
may also contribute to breast and ovarian tumori-
genesis. Thus, our finding lays the foundation for ad-
ditional investigation regarding the involvement of 
PP1 in cancer development. Furthermore, under-
standing the molecular mechanisms underlying the 
regulation of BRCA1 function by PP1 may provide 
new targets for the development of novel cancer 
therapeutics. 
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